CF mouse model reveals disease process
Marcus Mall, from the University of North Carolina in Chapel Hill, genetically modified mice to generate the typical symptoms of CF, something which...
Archives for April 26, 2004
Seconds out in fast-melt lawsuit
St Louis, USA-based KV Pharmaceutical says that the US District Court for the District of Minnesota has denied a motion for a preliminary injunction by two rival drug delivery companies in a patent dispute centring on its technology for...
Scie-Plas extends gel electrophoresis range
A new range of vertical gel units which have been designed for DNA sequencing and large format vertical gel electrophoresis applications, have been introduced by UK firm Scie-Plas, a subsidiary of Biochrom.
Fourth victim raises fears of SARS return
There are renewed concerns of another severe acute respiratory syndrome (SARS) epidemic after the Chinese Ministry of Health reported three more cases, including one death. This brings the current number of people with SARS-like symptoms in China to four.
EC mulls progress in European biotech
The European Commission has reported on its progress in building up Europe's competitiveness in the biotechnology and concludes that while positive steps have been taken, there is still much to be done, particularly with regard to intellectual...
Strakan starts trials of drug conjugate
Scottish pharmaceutical company Strakan has started a Phase I trial of a testosterone product that should overcome the limitations of delivering the drug by mouth.
Captisol hikes budesonide delivery to lungs
A formulation of the steroid drug budesonide, made using a solubility technology developed by US company CyDex, has outperformed one of the leading drugs for asthma on the market in a preclinical study.
Lonza teams up with RNA-TEC for oligo production
Switzerland's Lonza, one of the leading contract manufacturers of active pharmaceutical ingredients, has forged a collaboration with RNA-TEC of Belgium to provide broad-ranging contract production of oligonucleotides, a new class of drug that looks...